Oncobiologics (NASDAQ:OTLK) Director Yezan Munther Haddadin Purchases 29,000 Shares of Stock

Posted by Stanley Muller on Jun 4th, 2026

Oncobiologics, Inc. (NASDAQ:OTLK – Get Free Report) Director Yezan Munther Haddadin acquired 29,000 shares of Oncobiologics stock in a transaction dated Tuesday, June 2nd. The shares were bought at an average price of $0.83 per share, for a total transaction of $24,070.00. Following the transaction, the director owned 66,167 shares of the company’s stock, valued at approximately $54,918.61. The trade was a 78.03% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Oncobiologics Price Performance

Oncobiologics stock opened at $0.81 on Thursday. The stock has a market cap of $113.41 million, a P/E ratio of -0.69 and a beta of 0.96. Oncobiologics, Inc. has a 1 year low of $0.16 and a 1 year high of $3.39. The firm’s 50 day moving average price is $0.31 and its 200-day moving average price is $0.76.

Oncobiologics (NASDAQ:OTLK – Get Free Report) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.04). The firm had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $4.39 million. As a group, equities analysts expect that Oncobiologics, Inc. will post -0.51 EPS for the current year.

Institutional Investors Weigh In On Oncobiologics

Several large investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. increased its position in Oncobiologics by 74.1% during the first quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock valued at $126,000 after acquiring an additional 44,063 shares during the last quarter. AQR Capital Management LLC increased its position in Oncobiologics by 42.7% during the first quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock valued at $103,000 after acquiring an additional 25,351 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its position in Oncobiologics by 865.2% during the second quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock valued at $39,000 after acquiring an additional 21,941 shares during the last quarter. Institutional investors own 11.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on OTLK. Chardan Capital restated a “neutral” rating on shares of Oncobiologics in a research report on Wednesday, February 18th. Ascendiant Capital Markets reduced their price target on shares of Oncobiologics from $10.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, March 11th. HC Wainwright restated a “neutral” rating on shares of Oncobiologics in a research report on Wednesday, February 18th. BTIG Research restated a “neutral” rating on shares of Oncobiologics in a research report on Monday, May 18th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Oncobiologics in a research report on Friday, March 27th. One analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $4.50.

View Our Latest Analysis on Oncobiologics

About Oncobiologics

(Get Free Report)

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.